To the Editor We read with interest the article by Choi et al1 recently published in JAMA Oncology. The authors performed a nationwide historical population cohort study involving 24 156 treatment-naive patients with chronic hepatitis B who started treatment with entecavir or tenofovir disoproxil fumarate, comparing the 2 drugs in terms of the risk of hepatocellular carcinoma (HCC) and death or liver transplant. An interesting result was that tenofovir treatment was associated with a significantly lower risk of HCC compared with entecavir treatment.1 After reading this article carefully, we thought that 1 important issue should be discussed.
Zhang H, Zeng W. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. JAMA Oncol. Published online April 25, 20195(6):914–915. doi:10.1001/jamaoncol.2019.0641
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: